lebrikizumab
eli lilly
['advocate i']
truly dissapointet to yet again hear that advocate is an elegant trial . talk by prof.david jayne. is it elegant to design a trial, where patients in placebo arm is not treated according to soc? should we not demand more ? #eular2023 #aav